Antisense oligonucleotides targeting valosin-containing protein ameliorate muscle pathology and molecular defects in cell and mouse models of multisystem proteinopathy

Abstract

Background: Valosin-containing protein (VCP) related disease, also known as multisystem proteinopathy 1 (MSP1), is an autosomal dominant disease caused by gain-of-function pathogenic variants of the VCP gene. The disease presents with variable combinations of inclusion body myopathy, early-onset Paget's disease of bone, frontotemporal dementia and may also overlap with familial amyotrophic lateral sclerosis. There is currently no treatment for this progressive disease associated with early demise resulting from proximal limb girdle and respiratory muscle weakness. We hypothesise that regulating VCP hyperactivity to normal levels can reduce the disease pathology.

Main topics covered: In this study, we assessed the effect of antisense oligonucleotides (ASOs) specifically targeting the human VCP gene in the patient (R155H) iPSC-derived skeletal muscle progenitor cells (SMPCs). ASOs were well tolerated up to a concentration of 5 µM and significantly reduced VCP protein expression in the SMPCs by 48% (95% CI [39–56]). We also treated the transgenic mouse model of VCP disease with the overexpressed humanised VCP severe A232E pathogenic gene variant (VCP A232E mice) with weekly subcutaneous ASO injections starting from 6 months of age for 3 months. In the skeletal muscle of transgenic mice, ASOs resulted in 30% (95% CI [27–32]) knockdown of VCP protein compared with control ASO. The ASO-mediated reduction of VCP expression in muscle tissue was associated with improvement in autophagy flux and reduction in TAR DNA binding protein 43 (TDP-43) expression, hallmarks of VCP related MSP1. In addition, ASO-treated VCP A232E mice showed improvements in functional tests of muscle strength, such as rotarod and inverted screen test compared with mice treated with control ASO.

Conclusions: These results suggest that targeting VCP could be beneficial in preventing the progression of the VCP myopathy and hold promise for the treatment of patients with VCP related MSP1.

Keywords

A232E mouse model / induced pluripotent stem cell (IPSC) / skeletal muscle progenitor cell (SMPC) / VCP R155H cell model

References

[1] Korb MK, Kimonis VE, Mozaffar T. Multisystem proteinopathy: where myopathy and motor neuron disease converge. Muscle Nerve. 2021; 63(4): 442-454.

[2] Watts GD, Wymer J, Kovach MJ, et al. Inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia is caused by mutant valosin-containing protein. Nat Genet. 2004; 36(4): 377-381.

[3] Pfeffer G, Lee G, Pontifex CS, et al. Multisystem proteinopathy due to VCP mutations: a review of clinical heterogeneity and genetic diagnosis. Genes (Basel). 2022; 13(6): 963.

[4] Farpour F, Tehranzadeh J, Donkervoort S, et al. Radiological features of Paget disease of bone associated with VCP myopathy. Skeletal Radiol. 2012; 41(3): 329-337.

[5] Columbres RCA, Din S, Gibbs L, Kimonis V. Bone scan findings of Paget's disease of bone in patients with VCP multisystem proteinopathy 1. Sci Rep. 2024; 14(1): 5917.

[6] Al-Obeidi E, Al-Tahan S, Surampalli A, et al. Genotype-phenotype study in patients with valosin-containing protein mutations associated with multisystem proteinopathy. Clin Genet. 2018; 93(1): 119-125.

[7] Schiava M, Ikenaga C, Villar-Quiles RN, et al. Genotype-phenotype correlations in valosin-containing protein disease: a retrospective muticentre study. J Neurol Neurosurg Psychiatry. 2022.

[8] Meyer H, Weihl CC. The VCP/p97 system at a glance: connecting cellular function to disease pathogenesis. J Cell Sci. 2014; 127: 3877-3883.

[9] Wu R, Wei Z, Zhang L. Structural insight into mutations at 155 position of valosin containing protein (VCP) linked to inclusion body myopathy with Paget disease of bone and frontotemporal dementia. Saudi J Biol Sci. 2021; 28(4): 2128-2138.

[10] Niwa H, Ewens CA, Tsang C, Yeung HO, Zhang X, Freemont PS. The role of the N-domain in the ATPase activity of the mammalian AAA ATPase p97/VCP. J Biol Chem. 2012; 287(11): 8561-8570.

[11] Fernandez-Saiz V, Buchberger A. Imbalances in p97 co-factor interactions in human proteinopathy. EMBO Rep. 2010; 11(6): 479-485.

[12] Robinson SE, Findlay AR, Li S, et al. Elevated VCP ATPase activity correlates with disease onset in multisystem proteinopathy-1. Neurol Genet. 2024; 10(5):e200191.

[13] Hill SM, Wrobel L, Ashkenazi A, et al. VCP/p97 regulates Beclin-1-dependent autophagy initiation. Nat Chem Biol. 2021; 17(4): 448-455.

[14] Ju JS, Weihl CC. p97/VCP at the intersection of the autophagy and the ubiquitin proteasome system. Autophagy. 2010; 6(2): 283-285.

[15] Neumann M, Mackenzie IR, Cairns NJ, et al. TDP-43 in the ubiquitin pathology of frontotemporal dementia with VCP gene mutations. J Neuropathol Exp Neurol. 2007; 66(2): 152-157.

[16] Johnson JO, Mandrioli J, Benatar M, et al. Exome sequencing reveals VCP mutations as a cause of familial ALS. Neuron. 2010; 68(5): 857-864.

[17] Nandi P, DeVore K, Wang F, et al. Mechanism of allosteric inhibition of human p97/VCP ATPase and its disease mutant by triazole inhibitors. Commun Chem. 2024; 7(1): 177.

[18] Zhang T, Mishra P, Hay BA, Chan D, Guo M. Valosin-containing protein (VCP/p97) inhibitors relieve mitofusin-dependent mitochondrial defects due to VCP disease mutants. Elife. 2017; 6:e17834.

[19] Wang F, Li S, Wang TY, Lopez GA, Antoshechkin I, Chou TF. P97/VCP ATPase inhibitors can rescue p97 mutation-linked motor neuron degeneration. Brain Commun. 2022; 4(4):fcac176.

[20] Harley J, Hagemann C, Serio A, Patani R. TDP-43 and FUS mislocalization in VCP mutant motor neurons is reversed by pharmacological inhibition of the VCP D2 ATPase domain. Brain Commun. 2021; 3(3):fcab166.

[21] Cheng C, Weiss L, Leinonen H, et al. VCP/p97 inhibitor CB-5083 modulates muscle pathology in a mouse model of VCP inclusion body myopathy. J Transl Med. 2022; 20(1): 21.

[22] Leinonen H, Cheng C, Pitkanen M, et al. A p97/valosin-containing protein inhibitor drug CB-5083 has a potent but reversible off-target effect on phosphodiesterase-6. J Pharmacol Exp Ther. 2021; 378(1): 31-41.

[23] Scoles DR, Minikel EV, Pulst SM. Antisense oligonucleotides: a primer. Neurol Genet. 2019; 5(2):e323.

[24] Dhuri K, Bechtold C, Quijano E, et al. Antisense oligonucleotides: an emerging area in drug discovery and development. J Clin Med. 2020; 9(6):Epub20200626.

[25] Li D, Mastaglia FL, Fletcher S, Wilton SD. Precision medicine through antisense oligonucleotide-mediated exon skipping. Trends Pharmacol Sci. 2018; 39(11): 982-994.

[26] Wilton SD, Lloyd F, Carville K, et al. Specific removal of the nonsense mutation from the mdx dystrophin mRNA using antisense oligonucleotides. Neuromuscul Disord. 1999; 9(5): 330-338.

[27] Mercuri E, Darras BT, Chiriboga CA, et al. Nusinersen versus sham control in later-onset spinal muscular atrophy. N Engl J Med. 2018; 378(7): 625-635.

[28] Czhang oelho T, Marques W Jr, Dasgupta NR, et al. Eplontersen for hereditary transthyretin amyloidosis with polyneuropathy. JAMA. 2023; 330(15): 1448-1458.

[29] Bergmark BA, Marston NA, Prohaska TA, et al. Olezarsen for hypertriglyceridemia in patients at high cardiovascular risk. N Engl J Med. 2024; 390(19): 1770-1780.

[30] Cirak S, Arechavala-Gomeza V, Guglieri M, et al. Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study. Lancet. 2011; 378(9791): 595-605.

[31] Miller TM, Cudkowicz ME, Genge A, et al. Trial of antisense oligonucleotide tofersen for SOD1 ALS. N Engl J Med. 2022; 387(12): 1099-1110.

[32] Korobeynikov VA, Lyashchenko AK, Blanco-Redondo B, Jafar-Nejad P, Shneider NA. Antisense oligonucleotide silencing of FUS expression as a therapeutic approach in amyotrophic lateral sclerosis. Nat Med. 2022; 28(1): 104-116.

[33] Iyer AK, Schoch KM, Verbeck A, et al. Targeted ASO-mediated Atp1a2 knockdown in astrocytes reduces SOD1 aggregation and accelerates disease onset in mutant SOD1 mice. PLoS One. 2023; 18(11):e0294731.

[34] Kimonis VE, Fulchiero E, Vesa J, Watts G. VCP disease associated with myopathy, Paget disease of bone and frontotemporal dementia: review of a unique disorder. Biochim Biophys Acta. 2008; 1782(12): 744-748.

[35] Jaime OG, Arias J, Pavani S, Pyle AD, Hicks MR. SIX1+PAX3+ identify a progenitor for myogenic lineage commitment from hPSCs. Development. 2023; 150(14):dev201509.

[36] Borchin B, Chen J, Barberi T. Derivation and FACS-mediated purification of PAX3+/PAX7+ skeletal muscle precursors from human pluripotent stem cells. Stem Cell Reports. 2013; 1(6): 620-631.

[37] Hicks MR, Hiserodt J, Paras K, et al. ERBB3 and NGFR mark a distinct skeletal muscle progenitor cell in human development and hPSCs. Nat Cell Biol. 2018; 20(1): 46-57.

[38] Dalal S, Rosser MF, Cyr DM, Hanson PI. Distinct roles for the AAA ATPases NSF and p97 in the secretory pathway. Mol Biol Cell. 2004; 15(2): 637-648.

[39] Wojcik C, Yano M, DeMartino GN. RNA interference of valosin-containing protein (VCP/p97) reveals multiple cellular roles linked to ubiquitin/proteasome-dependent proteolysis. J Cell Sci. 2004; 117(Pt 2): 281-292.

[40] Jo M, Lee S, Jeon YM, Kim S, Kwon Y, Kim HJ. The role of TDP-43 propagation in neurodegenerative diseases: integrating insights from clinical and experimental studies. Exp Mol Med. 2020; 52(10): 1652-1662.

[41] Hasegawa M, Arai T, Nonaka T, et al. Phosphorylated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Ann Neurol. 2008; 64(1): 60-70.

[42] Neumann M, Sampathu DM, Kwong LK, et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science. 2006; 314(5796): 130-133.

[43] Tanida I, Ueno T, Kominami E. LC3 conjugation system in mammalian autophagy. Int J Biochem Cell Biol. 2004; 36(12): 2503-2518.

[44] Arhzaouy K, Papadopoulos C, Schulze N, Pittman SK, Meyer H. Weihl CC. VCP maintains lysosomal homeostasis and TFEB activity in differentiated skeletal muscle. Autophagy. 2019; 15(6): 1082-1099.

[45] Papadopoulos C, Kirchner P, Bug M, et al. VCP/p97 cooperates with YOD1, UBXD1 and PLAA to drive clearance of ruptured lysosomes by autophagy. EMBO J. 2017; 36(2): 135-150.

[46] Schlafli AM, Berezowska S, Adams O, Langer R, Tschan MP. Reliable LC3 and p62 autophagy marker detection in formalin fixed paraffin embedded human tissue by immunohistochemistry. Eur J Histochem. 2015; 59(2):2481.

[47] Redmann M, Benavides GA, Berryhill TF, et al. Inhibition of autophagy with bafilomycin and chloroquine decreases mitochondrial quality and bioenergetic function in primary neurons. Redox Biol. 2017; 11: 73-81.

[48] Klickstein JA, Johnson MA, Antonoudiou P, et al. ALS-related p97 R155H mutation disrupts lysophagy in iPSC-derived motor neurons. Stem Cell Reports. 2025; 20(5):102478.

[49] Custer SK, Neumann M, Lu H, Wright AC, Taylor JP. Transgenic mice expressing mutant forms VCP/p97 recapitulate the full spectrum of IBMPFD including degeneration in muscle, brain and bone. Hum Mol Genet. 2010; 19(9): 1741-1755.

[50] Llewellyn KJ, Nalbandian A, Weiss LN, et al. Myogenic differentiation of VCP disease-induced pluripotent stem cells: a novel platform for drug discovery. PLoS One. 2017; 12(6):e0176919.

[51] Yang H, Tan JX. Lysosomal quality control: molecular mechanisms and therapeutic implications. Trends Cell Biol. 2023; 33(9): 749-764.

[52] Zoncu R, Perera RM. Built to last: lysosome remodeling and repair in health and disease. Trends Cell Biol. 2022; 32(7): 597-610.

[53] Kravic B, Bionda T, Siebert A, et al. Ubiquitin profiling of lysophagy identifies actin stabilizer CNN2 as a target of VCP/p97 and uncovers a link to HSPB1. Mol Cell. 2022; 82(14): 2633-2649.

[54] Ferrari V, Cristofani R, Cicardi ME, et al. Pathogenic variants of Valosin-containing protein induce lysosomal damage and transcriptional activation of autophagy regulators in neuronal cells. Neuropathol Appl Neurobiol. 2022; 48(5):e12818.

[55] Zhang X, Gui L, Zhang X, et al. Altered cofactor regulation with disease-associated p97/VCP mutations. Proc Natl Acad Sci USA. 2015; 112(14): E1705-14.

[56] Anderson DJ, Le Moigne R, Djakovic S, et al. Targeting the AAA ATPase p97 as an approach to treat cancer through disruption of protein homeostasis. Cancer Cell. 2015; 28(5): 653-665.

[57] Lee YS, Klomp JE, Stalnecker CA, et al. VCP/p97, a pleiotropic protein regulator of the DNA damage response and proteostasis, is a potential therapeutic target in KRAS-mutant pancreatic cancer. Genes Cancer. 2023; 14: 30-49.

[58] Moriyama H, Yokota T. Recent progress of antisense oligonucleotide therapy for superoxide-dismutase-1-mutated amyotrophic lateral sclerosis: focus on tofersen. Genes (Basel). 2024; 15(10): 1342.

[59] Takeuchi T, Maeta K, Ding X, et al. Sustained therapeutic benefits by transient reduction of TDP-43 using ENA-modified antisense oligonucleotides in ALS/FTD mice. Mol Ther Nucleic Acids. 2023; 31: 353-366.

[60] Finkel RS, Mercuri E, Darras BT, et al. Nusinersen versus sham control in infantile-onset spinal muscular atrophy. N Engl J Med. 2017; 377(18): 1723-1732.

[61] Bennett CF. Therapeutic antisense oligonucleotides are coming of age. Annu Rev Med. 2019; 70: 307-321.

[62] Ostergaard ME, Jackson M, Low A, et al. Conjugation of hydrophobic moieties enhances potency of antisense oligonucleotides in the muscle of rodents and non-human primates. Nucleic Acids Res. 2019; 47(12): 6045-6058.

[63] Tedesco B, Vendredy L, Adriaenssens E, et al. HSPB8 frameshift mutant aggregates weaken chaperone-assisted selective autophagy in neuromyopathies. Autophagy. 2023; 19(8): 2217-2239.

[64] Nalbandian A, Llewellyn KJ, Badadani M, et al. A progressive translational mouse model of human valosin-containing protein disease: the VCP(R155H/+) mouse. Muscle Nerve. 2013; 47(2): 260-270.

[65] Nalbandian A, Llewellyn KJ, Kitazawa M, et al. The homozygote VCP(R(1)(5)(5)H/R(1)(5)(5)H) mouse model exhibits accelerated human VCP-associated disease pathology. PLoS One. 2012; 7(9):e46308.

RIGHTS & PERMISSIONS

2025 The Author(s). Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.